检索结果-南通市图书馆

World Journal of gastrointestinal oncology 2025年第3期17卷 81-90页

作者： Hai-Tao Li Yun-Yun Du Zhen Huang Jin-Jin Li Jun Zhang department of gastrointestinal Surgery Nanchuan Hospital of Chongqing Medical UniversityChongqing 408400China department of oncology Nanchuan Hospital of Chongqing Medical UniversityChongqing 408400China department of gastrointestinal Surgery The First Affiliated Hospital of Chongqing Medical UniversityChongqing 400016China

BACKGROUND For patients with advanced gastrointestinal stromal tumors(GISTs)carrying the ckit exon 11 mutation,imatinib(IM)at a standard dosage of 400 mg per day is the preferred first-line *** cases where treatment with IM fails,there is an urgent need for a more precise assessment method to determine whether to switch therapies or escalate the IM *** approach will enhance clinical decision-making and optimize patient *** To investigate IM plasma concentration’s role in second-line treatment decisions for c-kit 11-mutated advanced GISTs post-IM *** Patients with advanced GIST harboring c-kit 11 mutation who experienced failure with IM 400 mg per day as first-line treatment at our hospital were retrospectively *** were categorized into a low plasma(LP)concentration group(LP group,0.05).For the HP group(n=47),Group B(n=18)had a higher DCR and longer PFS than Group A(n=29)(P=0.008 and P=0.03,respectively).No difference in OS was observed between the two subgroups(P>0.05).CONCLUSION Increasing IM dosage for c-kit 11-mutated advanced GISTs post-IM failure may prolong OS if plasma concentration is<1100 ng/*** tyrosine kinase inhibitors may improve DCR and PFS if≥1100 ng/mL.

关键词： gastrointestinal stromal tumor C-kit exon 11 Imatinib Plasma concentration Second-line treatment

Impact of triglyceride-glucose index on the long-term prognosis of advanced gastric cancer patients receiving immunotherapy combined with chemotherapy

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2025年第5期31卷 68-83页

作者： Zhi-Yuan Yao Xiao Ma Yong-Zheng Cui Jie Liu Zheng-Xiang Han Jun Song department of oncology The Affiliated Hospital of Xuzhou Medical CollegeXuzhou 221000Jiangsu ProvinceChina department of oncology The Second Affiliated Hospital of Nanjing Medical UniversityNanjing 210008Jiangsu ProvinceChina department of Radiotherapy The Affiliated Hospital of Xuzhou Medical CollegeXuzhou 221000Jiangsu ProvinceChina department of gastrointestinal Surgery The Affiliated Hospital of Xuzhou Medical CollegeXuzhou 221000Jiangsu ProvinceChina

BACKGROUND Gastric cancer(GC)is the fifth most common malignancy and the third leading cause of death *** advancements in immunotherapies,patient prognosis remains poor,necessitating the identification of key prognostic factors to optimize the treatment *** resistance,as indicated by the triglyceride glucose(TyG)index,is increasingly recognized for its impact on cancer progression and immune modulation,and its potential role in GC prognosis is of particular *** To investigate whether the TyG index,a surrogate marker of insulin resistance,can predict the prognosis of patients with advanced GC receiving immunotherapy combined with *** This retrospective study included 300 patients with advanced GC who received sintilimab combined with *** patients were categorized into two groups according to high or low TyG index,and independent prognostic factors for overall survival(OS)were determined using Cox proportional hazards regression analysis,which led to the development of a nomogram *** Of the included patients,136 had a high TyG index and 164 had a low TyG *** median progression-free survival of the high TyG index group was significantly longer than that of the low TyG index ***,the median OS of the high TyG index group was significantly longer than that of the low TyG index *** ob-jective response and disease control rates in the two groups were 18.38%vs 9.15%and 58.82%vs 46.95%,*** significant difference was noted in the incidence of adverse reactions at any level between the two groups(P>0.05).In multivariate analysis,the Eastern Cooperative oncology Group score,programmed cell death ligand 1 expression,and TyG index acted as independent prognostic factors for *** these factors,the hazard ratio of the TyG index was 0.36(95%confidence interval:0.36-0.55,P<0.001),and the nomogram model re-emphasized its importance as the main predictor of patient prognos

关键词： Triglyceride glucose index Gastric cancer Sintilimab Prognostic model Efficacy Safety

Assessment of new pathological markers in early stage colon cancer:Insights and limitations

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of gastrointestinal oncology 2025年第3期17卷 113-121页

作者： Bulent Erdogan Fatma Elif UsturalıKeskin ErkanÖzcan Ahmet Küçükarda Ali Kaan Güren Osman Köstek Bekir Muhammet Hacioglu Hilmi Kodaz department of medical oncology Division of Medical OncologyDepartment of Internal MedicineTrakya University School of MedicineEdirne 22000Türkiye department of Pathology Trakya University School of MedicineTrakya UniversityEdirne 22000Türkiye Division of medical oncology Trakya University School of MedicineEdirne 22000Türkiye Division of medical oncology Department of Internal MedicineTrakya University School of MedicineEdirne 22000Türkiye Division of medical oncology Department of Internal MedicineMarmara University School of MedicineMarmara UniversityIstanbul 34000Türkiye Division of medical oncology Department of Internal MedicineMarmara University School of MedicineIstanbul 34000Türkiye department of medical oncology Acibadem Eskisehir HospitalEskisehir 26130Türkiye

BACKGROUND The decision to administer adjuvant chemotherapy to patients with local stage depends on specific high-risk features that are T4 tumor stage,presence of perineural invasion,lymphovascular invasion,poorly differentiated tumor histology,inadequate lymph node sampling(fewer than 12 lymph nodes),and evidence of tumor perforation or ***-stroma ratio,tumor infiltrating lymphocytes(TIL),Crohn-like reaction(CLR),desmoid reaction,poorly differentiated clusters(PDC)are new pathological markers that are being *** To examine the relationship between new pathological markers and defined high METHODS We evaluated 155 patients with the diagnosis stage I and II colorectal cancer between the years 2007 and 2021 who were treated at Trakya University Hospital,department of medical *** divided those with and without high-risk factors into two *** examined the relationship of new pathological markers with these groups and with pathological markers in risk *** There was no statistically significant correlation between presence of TIL,presence of PDC,presence of tumor budding,presence of CLR,presence of desmoid reaction and low and high-risk groups according to the degree of those with PDC(P=0.82,P=0.51,P=0.77,P=0.37,P=0.83,respectively).In addition,no statistically significant correlation was found between the tumor-stroma ratio and low and high risk groups(P=0.80).We found a statistically significant correlation between the presence of PDC and the presence of PDC grade 3 and T stage(P=0.001,P=0.001,respectively).It was determined that the presence of PDC and the frequency of grade 3 PDC increased with the advanced T *** No relationship was found between the presence of new pathological markers and high-low risk *** we examined the relationship between new and old pathological markers,only the frequency of detection of PDC and PDC grade 3 was found to be correlated with advanced T stage.

关键词： Colon cancer Early stage Risk factors New pathological markers Tumor-stroma ratio Tumor infiltrating lymphocytes Crohn-like reaction Desmoid reaction Poorly differentiated clusters

Is intraperitoneal isoperistaltic side-to-side anastomosis a safe surgical procedure in radical colon cancer surgery

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of gastrointestinal oncology 2025年第3期17卷 133-143页

作者： Bin Wu Jing-Tao Zhu He-Xin Lin Yu-Hua Dai Tian-Sheng Lin An-Le Huang Yi-Nan Chen Yong-Wen Li Hai-Bin Wang Yi-Fu Chen Dong-Han Chen Huang-Dao Yu Jun You Qing-Qi Hong department of gastrointestinal oncology Surgery The First Affiliated Hospital of Xiamen UniversitySchool of MedicineXiamen UniversityXiamen 361003Fujian ProvinceChina

BACKGROUND Colorectal cancer,one of the most common malignancies,is primarily treated through *** the widespread use of laparoscopy,gastrointestinal reconstruction remains a key area of *** choice between intraperitoneal anastomosis(IA)and extraperitoneal anastomosis(EA)remains a subject of considerable *** study uses intraperitoneal isoperistaltic side-to-side anastomosis(IISSA)with hand-sewn closure of the common opening to evaluate its safety and short-term *** is hypothesized that this technique may offer better short-term outcomes than *** To investigate the safety and short-term outcomes of IISSA with hand-sewn closure of the common opening compared to *** Patients who underwent laparoscopic radical colon cancer surgery between January 2018 and June 2022 at the First Affiliated Hospital of Xiamen University were retrospectively ***,postoperative,and pathological features of the IA and EA groups were observed before and after propensity score *** with right-sided and left-sided colon cancer were separated,each further divided into IA and EA groups(R-IA vs R-EA for right-sided,L-IA vs L-EA for left-sided),for stratified analysis of the aforementioned *** After propensity score matching,63 pairs were matched in each *** surgical characteristics,the IA group exhibited less blood loss and shorter incisions than the EA *** postoperative recovery,the IA group showed earlier recovery of gastrointestinal ***,the IA group had greater lymph node *** to the R-EA group,the R-IA group experienced reduced blood loss,shorter assisted incisions,earlier recovery of gastrointestinal functions and greater lymph node *** compared to the L-EA group,the L-IA group demonstrated earlier postoperative anal exhaust and defecation,along with a reduced length of *** postoperative complications,no statistically signific

关键词： Colon cancer Laparoscopic surgery Intraperitoneal anastomosis Extraperitoneal anastomosis Isoperistaltic sideto-side anastomosis Hand-sewn

Improved treatment of colorectal liver metastases by early response evaluation and regimen adjustment: a prospective study of clinical functional MR-based modeling

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Biology & Medicine 2025年第02期 166-176页

作者： Wenhua Li Huan Zhang Zhe Gong Yue Li Zhiyu Chen Xiaodong Zhu Mingzhu Huang Zhe Zhang Chenchen Wang Lixin Qiu Qirong Geng Jinjia Chang Xiaoying Zhao Xuedan Sheng Wen Zhang Tong Tong Weijian Guo department of medical oncology Fudan University Shanghai Cancer Center department of oncology Shanghai Medical College Fudan University department of Radiology Fudan University Shanghai Cancer Center department of Radiation oncology Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences

Objective: The aim of the study was to evaluate the feasibility of functional MR in predicting the clinical response to chemotherapy in patients with colorectal liver metastases(CLM).Methods: A total of 196 eligible patients were enrolled in the study between August 2016 and January 2023. Functional MR was performed at baseline and after one cycle of chemotherapy. The diffusion kurtosis radiomic texture features were extracted and a signature model was built using the R package. The initial 100 cases were designated as the training set, the following 48 cases were designated as the validation set, and the final 48 cases were designated as the intervention validation ***: Good performance for the response prediction(AUC = 0.818 in the training set and 0.755 in the validation set) was demonstrated. The objective response rates(ORRs) in the high-risk subgroup were significantly lower than the low-risk subgroup in the training and validation sets. Worse progression-free survival and overall survival rates were noted in the high-risk population. In the intervention set 22.9%(11/48) of the chemotherapy regimens for patients were changed in response to the model-predicted results and the ORR reached 77.1%(37/48), which was significantly higher than the training and validation sets [47.97%(71/148); P = 0.000].Conclusions: A functional MR signature effectively predicted the chemotherapy response and long-term survival. The adjustment of the regimen guided by the model significantly improved the ORR.

关键词：

Combination therapy strategy based on selective internal radiation therapy as conversion therapy for inoperable giant hepatocellular carcinoma:A case report

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

World Journal of gastrointestinal oncology 2025年第3期17卷 410-417页

作者： Ming-Zhi Hao Hai-Lan Lin Yu-Bin Hu Qi-Zhong Chen Zhang-Xian Chen Lin-Bin Qiu Duan-Yu Lin Hui Zhang De-Chun Zheng Zhu-Ting Fang Jing-Feng Liu department of Tumor Interventional Radiology Clinical Ocology School of Fujian Medical UniversityFujian Cancer HospitalFuzhou 350014Fujian ProvinceChina department of oncology and Vascular Interventional Radiology Clinical Oncology School of Fujian Medical UniversityFuzhou 350014Fujian ProvinceChina department of Nuclear Medicine Clinical Oncology School of Fujian Medical UniversityFuzhou 350014Fujian ProvinceChina department of Hepatopancreatobiliary Surgical oncology Clinical Oncology School of Fujian Medical UniversityFujian Cancer HospitalFuzhou 350014Fujian ProvinceChina department of Radiology Clinical Oncology School of Fujian Medical UniversityFujian Cancer HospitalFuzhou 350014Fujian ProvinceChina department of oncology and Vascular Interventional Radiology Clinical Oncology School of Fujian Medical UniversityFujian Cancer HospitalFuzhou 350014Fujian ProvinceChina department of Hepatobiliary Surgery Clinical Oncology School of Fujian Medical UniversityFujian Cancer HospitalFuzhou 350014Fujian ProvinceChina

BACKGROUND Hepatocellular carcinoma(HCC)has become a growing health concern *** invasion and high tumor burden are key factors limiting the curative effect of selective internal radiation therapy(SIRT).CASE SUMMARY This case study reports a 49-year-old woman who was diagnosed with China Liver Cancer Staging(CNLC)IIIa HCC and>15 cm tumor ***,due to insufficient future liver remnant and vascular invasion,the tumor was unresectable;however,radical hepatectomy was performed after successful conversion therapy with SIRT using yttrium-90(90Y)resin microspheres followed by hepatic arterial infusion chemotherapy(HAIC)with tyrosine kinase inhibitor(TKI)and anti-programmed death-1(PD-1)*** using 90Y resin microspheres was given by the right hepatic artery and chemoembolization was simultaneously performed in the tumor’s feeding vessels from the right diaphragmatic *** was followed every three weeks with lenvatinib and *** 4 months post-SIRT,the tumor was downstaged to CNLC Ib and the patient successfully underwent *** histopathological examination of the resected specimen showed extensive *** This case study provides evidence for an integrated treatment strategy combining SIRT and HAIC with TKI and anti-PD-1 antibodies for patients with large HCC and microvascular *** confirmatory trials are required in the future.

关键词： Selective internal radiation therapy Hepatic arterial infusion chemotherapy Yttrium-90 resin microspheres Hepatocellular carcinoma Conversion therapy Case report

Ubiquitin-specific protease 1 facilitates tumor immune escape from natural killer cells and predicts the prognosis in small cell lung cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

oncology Research 2025年第1期33卷 213-224页

作者： SHIQIN JIANG YICHUN TANG FENG MA YUCHUN NIU LEI SUN department of Clinical Pharmacy Shenzhen Hospital of Integrated Traditional Chinese and Western MedicineShenzhen518104China department of Pathology Zhujiang HospitalSouthern Medical UniversityGuangzhou510280China department of Radiation oncology The First People’s Hospital of FoshanFoshan528000China department of oncology The First Affiliated Hospital of Jinan UniversityJinan UniversityGuangzhou510630China department of oncology The First Dongguan Affiliated HospitalGuangdong Medical UniversityDongguan523721China

Objective:Small cell lung cancer(SCLC)is commonly recognized as the most fatal lung cancer *** substantial advances in immune checkpoint blockade therapies for treating solid cancers,their benefits are limited to a minority of patients with *** the present study,novel indicators for predicting the outcomes and molecular targets for SCLC treatment were ***:We conducted bioinformatics analysis to identify the key genes associated with tumor-infiltrating lymphocytes in *** functional role of the key gene identified in SCLC was determined both in vitro and in ***:A significant correlation was observed between patient survival and CD56dim natural killer(NK)cell ***,we noted that the hub gene ubiquitin-specific protease 1(USP1)is closely correlated with both CD56dim NK cells and overall survival in *** analysis revealed that USP1 is upregulated in *** addition,gene set enrichment analysis revealed that USP1 overexpression hinders NK cell-mediated immune *** co-cultivating NK-92 cells with SCLC cells,we demonstrated that NK cell cytotoxicity against SCLC could be improved either via USP1 knock-down or pharmacological ***,using a nude-mice xenograft tumor model,we noted that USP1 inhibition effectively suppressed tumor proliferation and increased the expression of NK cell-associated ***:Our study findings highlight the importance of NK cells in regulating ***1 overexpression can inhibit NK cell-mediated immunity;therefore,USP1 may serve not only as a prognostic biomarker but also as a potential molecular target of SCLC therapy.

关键词： Ubiquitin-specific protease 1(USP1) Natural killer(NK)cell Small cell lung cancer(SCLC) Prognosis Immune escape

Erianin inhibits the proliferation of lung cancer cells by suppressing mTOR activation and disrupting pyrimidine metabolism

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Biology & Medicine 2025年第02期 144-165页

作者： Lili Yan Yanfen Liu Yufei Huang Xiaoyu Sun Haiyang Jiang Jie Gu Jing Xia Xueni Sun Xinbing Sui School of Pharmacy and department of medical oncology The Affiliated Hospital of Hangzhou Normal University Hangzhou Normal University department of gastrointestinal & Pancreatic Surgery Key Laboratory of Gastroenterology of Zhejiang Province Zhejiang Provincial People's Hospital Affiliated People's Hospital Hangzhou Medical College

Objective: Erianin has potential anticancer activities, especially against lung cancer. The specific mechanisms underlying the anticancer effects, including the molecular targets and signaling pathways in lung cancer, remain poorly understood and necessitate further ***: Lung cancer cell viability was evaluated using the CCK-8 assay. Flow cytometry was used to examine the effects of erianin on apoptosis and cell cycle progression. m RNA sequencing and metabolomics analysis were utilized to explore erianin-induced biological changes. Potential targets were identified and validated through molecular docking and Western blot analysis. The roles of mammalian target of rapamycin(m TOR) and carbamoyl-phosphate synthetase/aspartate transcarbamylase/dihydroorotase(CAD) in erianin-induced growth inhibition were studied using gene overexpression/knockdown techniques with uridine and aspartate supplementation confirming pyrimidine metabolism involvement. Additionally, lung cancer-bearing nude mouse models were established to evaluate the anti-lung cancer effects of erianin in ***: Erianin significantly inhibits the proliferation of lung cancer cells, induces apoptosis, and causes G2/M phase cell cycle arrest. Integrative analysis of m RNA sequencing and metabolomics data demonstrated that erianin disrupts pyrimidine metabolism in lung cancer cells. Notably, uridine supplementation mitigated the inhibitory effects of erianin, establishing a connection between pyrimidine metabolism and anticancer activity. Network pharmacology analyses identified m TOR as a key target of erianin. Erianin inhibited m TOR phosphorylation, thereby blocking downstream effectors(S6K and CAD), which are essential regulators of pyrimidine ***: Erianin is a promising therapeutic candidate for lung cancer. Erianin likely inhibits lung cancer cell growth by disrupting pyrimidine metabolism by suppressing m TOR activation.

关键词：

Combination of fruquintinib with venetoclax for the treatment of colorectal cancer

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

oncology Research 2025年第1期33卷 225-234页

作者： WEI ZHANG WEICHENG WANG RUI WANG XIAO HAN LIJUN ZHU WENJIE GUO YANHONG GU department of oncology The First Affiliated Hospital of Nanjing Medical UniversityNanjing210029China State Key Laboratory of Pharmaceutical Biotechnology School of Life SciencesNanjing UniversityNanjing210023China department of oncology The Affiliated Taizhou People’s Hospital of Nanjing Medical UniversityTaizhou225300China

Background:As a novel blocker of vascular endothelial growth factor receptor(VEGFR),fruquintinib has been approved for treating colorectal cancer(CRC).However,its dosage and therapeutic efficacy are limited by its widespread adverse ***,recognized as the initial inhibitor of B-cell lymphoma protein 2(BCL2),has shown potential in boosting the effectiveness of immunotherapy against *** study investigated the efficacy and mechanisms of fruquintinib combined with venetoclax in treating *** and Materials:We developed a colon cancer mouse model with the CT26 colon cell line to demonstrate fruquintinib and venetoclax’s efficacy against *** we employed various techniques to evaluate different aspects of the experimental *** was used to detect cell proliferation and angiogenesis in tumor *** blot analysis was utilized to examine the occurrence of cell apoptosis,and flow cytometry to quantitate immune cells within the tumor ***,immunofluorescence was employed to measure cytokine ***:The strongest inhibition on tumor growth was achieved by the combination of fruquintinib with venetoclax,as opposed to individual drug *** was found to amplify the impact of fruquintinib,leading to decreased cancer cell proliferation,increased cancer cell apoptosis,lowered angiogenesis,better vascular structure normalization,and improved immune cell ***:Our findings indicate that the addition of venetoclax enhances the impact of fruquintinib on vascular normalization and modulation of the tumor immune *** study presents the justification for utilizing the fruquintinib and venetoclax combination in treating *** holds promise in being assimilated into anticancer medications for CRC.

关键词： Colorectal cancer(CRC) B-cell lymphoma protein 2(BCL2) Venetoclax Vascular endothelial growth factor receptor(VEGFR) Fruquintinib Anti-angiogenesis Immunotherapy

Colony-stimulating factor 3 and its receptor promote leukocyte immunoglobulin-like receptor B2 expression and ligands in gastric

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of gastrointestinal oncology 2025年第2期17卷 198-210页

作者： Long Wang Qi Wu Zong-Wen Zhang Hui Zhang Hui Jin Xin-Liang Zhou Jia-Yin Liu Dan Li Yan Liu Zhi-Song Fan department of oncology The Fourth Hospital of Hebei Medical UniversityShijiazhuang 050011Hebei ProvinceChina

BACKGROUND Colony-stimulating factor 3(CSF3)and its receptor(CSF3R)are known to promote gastric cancer(GC)growth and ***,their effects on the immune microenvironment remain *** analysis indicated a potential link between CSF3R expression and the immunosuppressive receptor leukocyte immunoglobulin-like receptor B2(LILRB2)in *** hypothesized that CSF3/CSF3R may regulate LILRB2 and its ligands,angiopoietin-like protein 2(ANGPTL2)and human leukocyte antigen-G(HLA-G),contributing to *** To investigate the relationship between CSF3/CSF3R and LILRB2,as well as its ligands ANGPTL2 and HLA-G,in *** Transcriptome sequencing data from The Cancer Genome Atlas were analyzed,stratifying patients by CSF3R *** expressed genes and immune checkpoints were ***(IHC)was performed on GC *** analyses of CSF3R,LILRB2,ANGPTL2,and HLA-G were conducted using The Cancer Genome Atlas data and IHC *** cells were treated with CSF3,and expression levels of LILRB2,ANGPTL2,and HLA-G were measured by quantitative reverse transcriptase-polymerase chain reaction and western *** Among 122 upregulated genes in high CSF3R expression groups,LILRB2 showed the most significant *** results indicated high expression of LILRB2(63.0%),ANGPTL2(56.5%),and HLA-G(73.9%)in GC *** positive correlations existed between CSF3R and LILRB2,ANGPTL2,and HLA-G mRNA levels(P0.05).CSF3 increased LILRB2,ANGPTL2,and HLA-G expression in GC *** nuclear ribonucleoprotein H1 modulation significantly altered their expression,impacting CSF3’s regulatory *** The CSF3/CSF3R pathway may contribute to immunosuppression in GC by upregulating LILRB2 and its ligands,with heterogeneous nuclear ribonucleoprotein H1 playing a regulatory role.

关键词： Gastric cancer Immunosuppressive receptor Colony-stimulating factor 3 Colony-stimulating factor 3 receptor Leukocyte immunoglobulin-like receptor B2 Angiopoietin-like protein 2 Human leukocyte antigen-G Heterogeneous nuclear ribonucleoprotein H1